ArticleMedicine2025
Two-sample Mendelian randomization analysis of 91 circulating inflammatory protein levels and meningioma.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Two-way Mendelian randomisation study of inflammatory factors and the risk of meningioma.Translational neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are prevalent central nervous system tumors with unclear etiological mechanisms. Due to their location outside the blood-brain barrier, they may be susceptible to systemic inflammatory responses. This study aimed to explore the causal relationship between 91 inflammatory proteins and meningiomas through 2-sample Mendelian randomization (MR). Using genome-wide association studies data from 14,824 participants, single nucleotide polymorphisms associated with inflammatory proteins were selected as instrumental variables. Meningioma data were obtained from a Finnish database (1316 cases and 3,13,392 controls). The inverse-variance weighted method assessed associations, with sensitivity analyses to ensure robustness. Reverse MR examined meningioma impact on inflammatory proteins. Forward MR analysis showed elevated Fms-related tyrosine kinase 3 ligand (FLT3L) levels correlated with reduced meningioma risk (OR = 0.72, 95% CI = 0.61-0.85, P < .001). Reverse MR suggested meningiomas might lower plasma FLT3L, C-X-C motif chemokine 11, adenosine deaminase, and hepatocyte growth factor levels. FLT3L may play a protective role in meningiomas, warranting further research on inflammatory proteins for prevention and treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.